Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of treatment of acute HIV infection with a once daily regimen of
Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are:
1. To determine the safety and tolerability, and the virologic and immunologic efficacy of
FTC, TDF, and efavirenz given once daily to patients with acute HIV infection.
2. To assess the impact of once daily therapy combined with a standardized adherence
program on treatment adherence, virologic suppression, and rate of viral load decline in
blood and infectious fluids (semen, cervico-vaginal secretions).
3. To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents
among persons diagnosed with acute HIV infection in the Southeastern United States.
Phase:
Phase 4
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Bristol-Myers Squibb Gilead Sciences
Treatments:
Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir